Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.65 |
| ▸ | RAB9A | P51151 | 11/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MITF | O75030 | 1/20 | 0.65 |
| ▸ | KDM5A | P29375 | 1/20 | 0.65 |
| ▸ | KDM5C | P41229 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291859 | 1.00 | NPC1 (0.65) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14107253 | 0.85 | APP (0.54) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12291856 | 0.85 | APP (0.54) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2432402 | 0.85 | APP (0.56) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2434237 | 0.85 | APP (0.49) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2429956 | 0.85 | APP (0.56) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12291867 | 0.85 | APP (0.56) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2429079 | 0.85 | RAB9A (0.66) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2428682 | 0.85 | GAA (0.58) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12326371 | 0.82 | LMNA (0.43) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | claimed |
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8022075-B2 | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition | FUJIFILM RI PHARMA CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1956013-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | Fujifilm RI Pharma Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | APP, TTR, BACE1 | NPC1 533/4885RAB9A 3111/4885KDM4E 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.